Workflow
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
ArdelyxArdelyx(US:ARDX) Newsfilter·2024-05-16 12:01

Core Insights - Ardelyx, Inc. presented positive clinical data for XPHOZAH® (tenapanor) at the NKF 2024 Spring Clinical Meetings, highlighting its potential impact on managing hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis [1][3] Company Overview - Ardelyx is a biopharmaceutical company focused on developing innovative, first-in-class medicines to address significant unmet medical needs [1][14] - The company has two commercial products approved in the U.S., including IBSRELA® and XPHOZAH® [14] Product Information - XPHOZAH is the first and only phosphate absorption inhibitor approved by the FDA for reducing serum phosphorus in adults with CKD on dialysis [2][13] - It is administered as a single tablet taken twice daily and works by blocking phosphate absorption at the primary pathway [2][7] Clinical Data Highlights - A poster presentation indicated that adding tenapanor to sevelamer treatment improved phosphate control, as measured by average daily phosphate area under the curve (AUC) [3][4] - Another analysis showed that tenapanor's efficacy and safety were consistent across different age groups and comorbidities in dialysis patients [4] - A study on patient perception revealed that 80% of patients felt their phosphate management improved with tenapanor, leading to better adherence to therapy [5] Industry Context - Hyperphosphatemia is a prevalent condition among the 550,000 CKD patients on dialysis in the U.S., necessitating effective management strategies [9] - The KDIGO guidelines recommend lowering elevated phosphate levels to the normal range of 2.5-4.5 mg/dL [9]